ATE401887T1 - Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen - Google Patents

Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen

Info

Publication number
ATE401887T1
ATE401887T1 AT04715295T AT04715295T ATE401887T1 AT E401887 T1 ATE401887 T1 AT E401887T1 AT 04715295 T AT04715295 T AT 04715295T AT 04715295 T AT04715295 T AT 04715295T AT E401887 T1 ATE401887 T1 AT E401887T1
Authority
AT
Austria
Prior art keywords
agonist
connection
acting beta
active ingredients
long
Prior art date
Application number
AT04715295T
Other languages
English (en)
Inventor
Roberta Razzetti
Fiorella Pastore
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401887(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE401887T1 publication Critical patent/ATE401887T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04715295T 2003-02-27 2004-02-27 Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen ATE401887T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (de) 2003-02-27 2003-02-27 Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid

Publications (1)

Publication Number Publication Date
ATE401887T1 true ATE401887T1 (de) 2008-08-15

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715295T ATE401887T1 (de) 2003-02-27 2004-02-27 Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen

Country Status (32)

Country Link
US (1) US20070020190A1 (de)
EP (3) EP1452179A1 (de)
JP (1) JP2006519204A (de)
KR (1) KR20050104367A (de)
CN (2) CN100370986C (de)
AR (1) AR043419A1 (de)
AT (1) ATE401887T1 (de)
AU (1) AU2004216472B2 (de)
BR (1) BRPI0408047A (de)
CA (1) CA2517321A1 (de)
CY (1) CY1108360T1 (de)
DE (1) DE602004015260D1 (de)
DK (1) DK1603565T3 (de)
EA (1) EA008828B1 (de)
ES (1) ES2309503T3 (de)
HK (1) HK1087009A1 (de)
HR (1) HRP20050726A2 (de)
MA (1) MA27630A1 (de)
ME (1) MEP32208A (de)
MX (1) MXPA05009007A (de)
NO (1) NO20053959L (de)
NZ (1) NZ541997A (de)
PE (1) PE20050290A1 (de)
PL (1) PL377814A1 (de)
PT (1) PT1603565E (de)
RS (1) RS20050615A (de)
SA (1) SA04250122B1 (de)
SI (1) SI1603565T1 (de)
TN (1) TNSN05186A1 (de)
UA (1) UA82217C2 (de)
WO (1) WO2004075896A1 (de)
ZA (1) ZA200506820B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
JP2007501194A (ja) * 2003-08-05 2007-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ステロイドとβ模倣薬を含む吸入用薬剤
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
JP2009502997A (ja) * 2005-08-01 2009-01-29 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 噴霧投与用の長時間作用型ベータ２−アゴニストを含む医薬製剤
EP1948596B1 (de) * 2005-11-10 2011-10-19 Nicholas S. Bodor Sanfte anticholinerge ester
EP1971369B1 (de) * 2005-12-21 2009-08-19 MEDA Pharma GmbH & Co. KG Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
CA2650813A1 (en) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh New long-acting drug combinations for the treatment of respiratory diseases
EP1953143A1 (de) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von 8-Hydroxy-5-[(1R)-1-Hydroxy-2[[(1R)-2-(4-Methoxyphenyl)-1-Methylethyl]amino]ethyl]-2(1H)-Chinolinon-Monohydrochlorid
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
EP2534958A1 (de) 2007-12-14 2012-12-19 AeroDesigns, Inc Abgabe von Aerosol-sprühbaren Nahrungsmittelprodukten
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
WO2010136153A1 (en) * 2009-05-25 2010-12-02 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
WO2011136753A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
EP2593108A2 (de) * 2010-07-16 2013-05-22 Cilpa Limited Pharmazeutische zusammensetzungen mit r(+) budesonid und einem oder mehreren bronchodilatatoren
WO2012010854A1 (en) 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
PL2968312T3 (pl) * 2013-03-15 2018-08-31 Verona Pharma Plc Kombinacja leków
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
WO2016085933A1 (en) * 2014-11-24 2016-06-02 The Board Of Trustees Of The University Of Illinois Method of preventing or treating a pulmonary disease or condition
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1393721T3 (da) * 1997-03-20 2009-03-30 Schering Corp Doseringsform af pulveragglomerater
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
EP1595531A1 (de) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren

Also Published As

Publication number Publication date
SA04250122B1 (ar) 2009-03-11
PT1603565E (pt) 2008-10-06
DE602004015260D1 (de) 2008-09-04
CN101244063A (zh) 2008-08-20
AU2004216472B2 (en) 2009-08-06
ZA200506820B (en) 2006-11-29
HRP20050726A2 (en) 2006-02-28
SI1603565T1 (sl) 2008-10-31
JP2006519204A (ja) 2006-08-24
ES2309503T3 (es) 2008-12-16
PL377814A1 (pl) 2006-02-20
MXPA05009007A (es) 2005-10-18
CN100370986C (zh) 2008-02-27
HK1087009A1 (en) 2006-10-06
EP1603565B1 (de) 2008-07-23
NO20053959L (no) 2005-11-28
EP1452179A1 (de) 2004-09-01
EA200501108A1 (ru) 2006-04-28
EP1834643A2 (de) 2007-09-19
EA008828B1 (ru) 2007-08-31
MEP32208A (en) 2010-10-10
UA82217C2 (uk) 2008-03-25
EP1603565A1 (de) 2005-12-14
WO2004075896A1 (en) 2004-09-10
AU2004216472A1 (en) 2004-09-10
CY1108360T1 (el) 2014-02-12
US20070020190A1 (en) 2007-01-25
AR043419A1 (es) 2005-07-27
DK1603565T3 (da) 2008-11-10
BRPI0408047A (pt) 2006-02-14
NO20053959D0 (no) 2005-08-25
PE20050290A1 (es) 2005-05-26
KR20050104367A (ko) 2005-11-02
RS20050615A (en) 2007-09-21
EP1834643A3 (de) 2007-10-24
CN1753678A (zh) 2006-03-29
MA27630A1 (fr) 2005-11-01
TNSN05186A1 (en) 2007-06-11
NZ541997A (en) 2008-12-24
CA2517321A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
ATE401887T1 (de) Medikament enthaltend ein hochaktives langwirkendes beta-2-agonist in verbindung mit anderen wirkstoffen
DE60306851D1 (de) Behälter für Medikamentenlösung mit einem Kommunikationsverbinder
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
DE60331153D1 (de) Reboxetin enthaltende tablette mit verzögerter wirkstoffabgabe
ITMI20032473A1 (it) Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
DE60335807D1 (de) Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe
IL177869A0 (en) A stable pharmaceutical composition comprising an acid labile drug
HK1070266A1 (en) Liquid drug container
AU2003243750A8 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
DE60310935D1 (de) Aktive luer-verbindung mit membrane und behälter mit verbindung
DK1459737T3 (da) Granulat indeholdende syreustabilt kemisk middel i stor mængde
PT1633388E (pt) Formulações proteicas líquidas estabilizadas em recipientes farmacêuticos
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion
DE60136625D1 (de) Quetschbehälter mit regelbarer abgabevorrichtung
ZA200705119B (en) Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
AU2003232431A8 (en) A stable bicarbonate-based solution in a single container
AU2003230980A1 (en) Micelle delivery system loaded with a pharmaceutical agent
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
AU2003207461A1 (en) Drug mixture with enhanced dissolution rate
DE60301201D1 (de) Stauförderer mit verriegelbaren trägern
SI1594859T1 (sl) Indazolamidi z analgetsko aktivnostjo
ATE373473T1 (de) Inhalative lösungsformulierung mit einem tiotropiumsalz
ITMI20030972A1 (it) Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603565

Country of ref document: EP

REN Ceased due to non-payment of the annual fee